

## ABSTRACT

The present invention concerns the use of a PTHrP antagonist for preparing a pharmaceutical composition for treating renal cell carcinoma (RCC) in a mammal and in particular in a human subject. Advantageously, the invention is of particular interest for inhibiting or reducing tumour growth and / or metastasis formation in kidney cancer and its metastatic developments, in particular in the lung and the liver.